歌禮制藥-B(01672.HK)擬折價配股募資4.7億港元 加碼肥胖症藥物研發
格隆匯8月19日丨歌禮制藥-B(01672.HK)發佈公告,2025年8月19日(交易時段前),公司、補足賣方(即JJW12 Limited,由公司創辦人、董事會主席、執行董事兼行政總裁及控股股東之一吳勁梓全資擁有及爲控股股東之一)與配售代理(即花旗)訂立配售及認購協議,據此,(i)補足賣方同意出售,而配售代理同意作爲補足賣方代理,促使承配人(將爲專業、機構、企業或其他投資者)按每股股份16.45港元的價格購買補足賣方所持有的5240萬股股份,及(ii)補足賣方有條件同意認購,而公司有條件同意按配售價發行2882萬股新股份。
配售股份總數爲5240萬股,佔本公司於本公告日期已發行股份數目(即約9.636億股股份,不包括578.42萬股庫存股份)約5.44%。認購股份數目爲2882萬股,佔經配發及發行認購股份擴大後的股份約2.90%(不包括庫存股份)。配售價每股股份16.45港元較8月18日於聯交所所報的收市價每股股份18.26港元折讓約9.9%。認購股份將根據一般授權配發及發行。
緊隨配售及認購完成後,補足賣方的股權將由已發行股本(不包括庫存股份)的約53.38%減少至已發行股本(不包括庫存股份)的約49.45%及控股股東的總持股百分比將由已發行股本(不包括庫存股份)約62.21%減少至經配發及發行認購股份擴大後的已發行股本(不包括庫存股份)的約58.03%。認購所得款項總額預期合共約爲4.74億港元,而認購所得款項淨額(經扣除傭金及估計開支後)預期合共約爲4.68億港元。認購事項所得款項淨額中約90%建議用於其皮下注射多肽及口服多肽候選藥物有關的肥胖症臨牀試驗研發,而認購事項所得款項淨額中約10%建議用作營運資金及其他一般公司用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.